chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report received on 04 August 2007 from a health care professional. A  37 year old male patient received on 02 August 2007 first dose of Menactra (lot# U2366AA) into the left side (route and site of administration not reported); first dose of Typhim Vi (lot# Z1102-2) into the left side (route and site of administration not reported); first dose of IPOL (lot# Z0873-2) into the right side (route and site of administration not reported). Within 6 hours post vaccination, the patient experienced fever. The patient was also experiencing headache and left flank pain. He went to the ER on 04 August 2007 for evaluation and was released home. Fever was down to 102. The flank pain was reported to be better. White Blood Count (WBC) was high, chest x-ray (CXR) was clear, lungs were clear. The patient did not have illness at vaccination time and any known allergies (NKA). The patient's concomitant medications included: Omacor, Zetia and lescol. The patient did not have experience adverse event following prior vaccination. The patient had not recovered. Follow-up information was received on 25 September 2007 from the original reporting physician. Per the physician,"although we administered the vaccines to this patient, he did not return to our care for when he became ill." The physician was notified by telephone of the patient's illness and was not consulted regarding the patient's medical care; nor was he given access to the patient's medical records, "thus out knowledge of this case is from personal communication with the patient." The patient reported to the physician that as his illness progressed, he developed a severe but localized swelling at the site of the pneumococcal vaccination. Contrary to the medical history given at the time of the vaccinations on 02 August 2007, the patient has a previous "relatively recent" pneumococcal vaccination. Therefore, it was felt "this illness represented a severe Arthus-type reaction to that vaccine." The patient was treated with intravenous antibiotics and corticosteroids and made a "good recovery." Due to this new information, this case was upgraded to serious.
Pt was exposed to a child who had been vaccinated with rubella virus vaccine live.subsequently,the pt developed chronic fatigue synd symptoms consistent w/rubella viremia, @ confirmed w/ elevated titers. F/U O8MAR91: PT IS 40 Y.O. female.
Approximately 1 week after receiving the vaccine, I developed swelling and a large circular red rash at the injection site. The large red lesion around the injection site was initially itchy and is now tender to touch. There is also swelling and a slight hardness under the red lesion.
night sweats; nausea; body aches; chills; sleepiness; severe with slight fever; shakiness; brain fog; weakness; loss of weight; anxiety; This is a spontaneous report from a contactable consumer or other non hcp. A 76-years-old patient of an unspecified gender received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number -not reported), dose 2 via an unspecified route of administration on an unspecified date as DOSE 2, SINGLE (at 76-years age) for covid-19 immunisation. Medical history included celiacs, RA (rheumatoid arthritis), anemia, osteo-sarthritis, allergies all from an unknown date and unknown if ongoing. Concomitant medications included amlodipine (AMLODIPINE), fluticasone (FLUTICASONE), lamotrigine (LAMOTRIGINE), leflunomide (LEFLUNOMIDE) all were taken for an unspecified indication, start and stop date were not reported. Patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, lot number-unknown) via unspecified route of administration time in Left arm on 21Feb2021 at 06: 45 pm as DOSE 1, SINGLE for covid-19 immunization. The patient received vaccine at hospital. The patient not diagnosed with covid-19 prior to vaccination and did not tested post vaccination. The patient did not receive other vaccine in four weeks. The patient experienced night sweats, nausea, body aches, chills, sleepiness. for around 2 days after with lingering symptoms for a few days second shot, same reactions only more severe with slight fever and shakiness, have something like a brain fog, weakness, loss of weight, still experiencing symptoms but not as severe with anxiety and weakness on 23Feb2021 02:30 PM. The patient did not received treatment for all events. The outcome of all events was resolving.  No follow-up attempts are Possible. Information on lot/batch cannot be obtained.
pt recv vax 24MAR99 @ 2PM & early evening noticed raised red rash on arms, face, trunk;when awoke 5AM also had tingling of lips, dry palms & soles;itching palms, soles;
Pt presented to clinic  on 5/13/2021, with an angry red, swollen and warm to the touch right upper limb.   Redness and irritation near the injection site started  on 5/10/2021. Redness continued to increase in size over the next couple days.   Primary care provider examined patient's right upper limb.  Pt was placed on the following medications for cellulitis of right upper limb :  DICLOFENAC SODIUM--TOP 1% GEL;  SIG: APPLY 2 GRAMS TO AFFECTED AREA THREE TIMES A DAY AS NEEDED PAIN,  PROBIOTIC (ACIDOPHILLUS)--PO TAB;  SIG: TAKE ONE TABLET BY MOUTH EVERY DAY,  TRIMETHOPRIM/SULFA (DS)-PO 160/800MG TAB;  SIG: TAKE ONE TABLET BY MOUTH TWICE A DAY FOR 10 DAYS.
Severe Alopecia Areata which began to be noticeable on 1/20/20 with 50% hair loss and has continued until today 3/14/2021
17 yr. old patient received her third HPV shot. Arm was sore for 2 days resolved. Two weeks and two days later the arm got severe swollen, MD visit found cellulitis.
Mother states patient developed loss of taste and smell same day as vaccine administered on 2/12/22. Mother states patient had a 1-2 minute seizure on 2/13/22. Previous (2nd COVID Vaccine) given 11-17-21. PCP recommended patient to see neurologist to F/U on seizure and receive a second COVID-19 test (PCP)
a patient missed their second dose in the GARDASIL 9 series; No additional AE reported; This spontaneous report was received from a health care professional referring to a currently 25-year-old patient of unknown gender. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant therapies were not reported. It was confirmed that the patient was not enrolled in any program.   On an unknown date, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (strength, dose, frequency, route, lot# and expiration date were not provided) for prophylaxis.   On an unknown date, the patient missed the second dose in the hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) series (product dose omission issue). No additional information was reported to confirm the date of the missed dose or to clarify any additional information related to the adverse event (AE). No additional AE reported.
Diarrhea, bad rash/welts that is spreading, tired, lathargic, loss of appetite, excessive sweating and chills.
Moderna COVID-19 Vaccine EUA  Patient developed copious purulent vaginal discharge along with vaginitis. Patient notes "white bumps" on her legs and in her mouth. Sores in mouth are very painful and make it uncomfortable to talk.
Rash after receiving flu shot on 12/20/10 reported by mom. Gave BENADRYL. Nurse instructed her to call MD.
Narrative: COVID infection following COVID vaccine series 01/13, Pfizer, dose #1 (non Facility) 02/10, Pfizer, dose #2 (non Facility) 08/01 pt cc: headache, chills, fatigue, rhinorrhea exposure; unknown 08/06 COVID swab, result: detected 08/06 CXR impression: 1. Minimal left basilar opacity, likely atelectasis. 2. No focal lung consolidation or pleural effusion. 08/06 pt admitted to ED dx: COVID infection, LOS: 1 day, patient left AMA 08/07 DDIMER result: 1.02 08/07 TROPONIN I result: 0.024 08/07 PROCALCITONIN result: <0.05 08/07 CRP result: 3.029 08/12 clinically resolved 08/12 SARS-COV-2 LINEAGE result: AY .3 08/12 SARS-COV-2 CLADE result: 21A Delta 08/20 COVID swab, result: detected.
Day after immunization child presented with fever up to 102.8, inconsolable crying, decreased appetite.
24 hrs after injection upon taking NIASPAN 500 mg x 4, instantly got big chill and convulsions that lasted over an hour and I could not even call 911 - I tried!
This spontaneous report as received from a physician refers to a 2 month old patient of unknown gender. Medical history and current conditions were not reported. On 12-DEC-2014 the patient, who was 2 months old, was vaccinated with a dose of VARIVAX (Merck) (route, lot number and expiration date were not reported). Concomitant medication was not provided. No adverse effects were reported. Additional information has been requested.
he has been deaf since he got out; This is a spontaneous report from a contactable consumer (patient).  A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 16Jan2021 at single dose for COVID-19 immunization.  The patient medical history and concomitant medications were not reported. He has been a truck driver all his life. The patient reported that he has been deaf since he got out, on an unknown date. He stated that his heart doctor wanted him to take a nuclear test on 20Jan2021. Patient did not want to take a test if it will interfere with his shot and he wanted to know if this will interfere with his shot. The final outcome of the event was unknown. Information on the batch number has been requested.
MD ordered Proquad and Varicella for 12 month old.  Staff administered both vaccines. It was discovered later in a chart review that both vaccines were given together.
I have not received any vaccines since a flu shot in early 2000?s.  I have experienced a year long vaccine injury due to shedding (being around people who have taken the shot).  I am experiencing symptoms of blood clotting, nerve tingling , etc. for the past year. I was perfectly healthy before that.
Mild lower back pain over the preceding two day dramatically worsened to the point of rendering me nearly immobile. This serious back pain lasted for ~4 days, slowly improving.
2nd dose of fluzone high dose quadrivalent was administered 11 days after the first dose was given with no reported adverse event; Initial information received on 01-Feb-2022 regarding an unsolicited valid non-serious case received from an other health professional.  This case involves a 6 month old and unknown gender patient to whom 2nd dose of influenza quadrival a-b high dose hv vaccine [Fluzone high-dose quadrivalent] was administered 11 days after the first dose was given with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received the first dose of suspect influenza quadrival a-b high dose hv vaccine once (lot number and expiry date: unknown) via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date the patient received the second dose of the same vaccine once (lot: UT7376NA and expiry date: 30-Jun-2022) unk via unknown route in unknown administration site as prophylactic vaccination.  It was reported that the second dose of fluzone high dose quadrivalent was administered 11 days after the first dose was given (Inappropriate schedule of product administration, latency: unknown). The reporter enquired if there would be any harm to the baby as well as was asking for a suggestion if they needed to give another dose.   Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (2nd dose of fluzone high dose quadrivalent was administered 11 days after the first dose was given with no reported adverse event).  At time of reporting, the outcome was Unknown for the event 2nd dose of fluzone high dose quadrivalent was administered 11 days after the first dose was given with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
This spontaneous report was received from a nurse who referred to an unspecified number of patients of unknown demographics. No information regarding the patients' pertinent medical history, concomitant medications and drug reactions or allergies was provided. On unknown dates (reported as over the past year), the patients were vaccinated with improperly stored doses of PNEUMOVAX 23 (dose, route of administration, lot# and expiration dates were not reported) as prophylaxis. The vaccines were stored between 47 degrees Fahrenheit (F) and 77F (49F) for 8 hours and 30 minutes and between 32F and 35F (32F) for 16 hours and 30 minutes. No previous temperature excursions were reported. The excursions were detected by a data logger. No adverse effects were reported. No product quality complaint was involved. This is one of three reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1707USA005788: US-009507513-1707USA006075.
This spontaneous report as received from a medical assistant refers to a 5 year old patient. No information about medical history, drug reactions and allergies were specified. The reporter stated that on 04-AUG-2014 she inadvertently administered both ZOSTAVAX (lot # not reported0 subcutaneous and (Oka/Merck) VARIVAX (lot # dose, route not reported) to the 5 year old patient. No concomitant medications were reported. No adverse effects reported. There was no product quality complaint. Additional information has been requested.
Starting the day after the vaccine on Jan 1st 2022 my right arm was very sore. I was unable to reach fully, the by day 3 the pain went to my neck and then to my left arm. I am unable to sleep because of the pain. I have had a neck Exray I have been to my chiropractor several times and my doctor set me up with physical therapy, and I have gone 6 times so far and have tried Message therapy that helps for a short time. I have had chronic pain since Jan 1st 2022
Was fine after vaccine no arm pain. Two months later severe arm pain unable to lay on arm and move arm back or raise up high
pressure headache; fever; throbbing/pressure headache; could not lie on her bath tub because of her back pain; cough; sweating; vomited; was not able to eat anything; real sharp pain on her upper and lower back, pain in lower back; pain on lower abdomen; numbness of the fingers on her right hand; nauseous; 2nd dose of the vaccine given beyond 36 days; arm hurt; chills; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose of the vaccine given beyond 36 days), PAIN IN EXTREMITY (arm hurt), FEEDING DISORDER (was not able to eat anything), BACK PAIN (real sharp pain on her upper and lower back, pain in lower back) and ABDOMINAL PAIN LOWER (pain on lower abdomen) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001C21A and 036C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 01-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose of the vaccine given beyond 36 days), PAIN IN EXTREMITY (arm hurt) and CHILLS (chills). On 20-Jul-2021, the patient experienced FEEDING DISORDER (was not able to eat anything), BACK PAIN (real sharp pain on her upper and lower back, pain in lower back), ABDOMINAL PAIN LOWER (pain on lower abdomen), HYPOAESTHESIA (numbness of the fingers on her right hand), VOMITING (vomited) and NAUSEA (nauseous). On 21-Jul-2021, the patient experienced HYPOKINESIA (could not lie on her bath tub because of her back pain), COUGH (cough), HYPERHIDROSIS (sweating) and HEADACHE (throbbing/pressure headache). On an unknown date, the patient experienced HEAD DISCOMFORT (pressure headache) and PYREXIA (fever). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at a dose of 1 dosage form. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2nd dose of the vaccine given beyond 36 days), PAIN IN EXTREMITY (arm hurt), FEEDING DISORDER (was not able to eat anything), BACK PAIN (real sharp pain on her upper and lower back, pain in lower back), ABDOMINAL PAIN LOWER (pain on lower abdomen), HYPOAESTHESIA (numbness of the fingers on her right hand), HEAD DISCOMFORT (pressure headache), HYPOKINESIA (could not lie on her bath tub because of her back pain), COUGH (cough), HYPERHIDROSIS (sweating), VOMITING (vomited), CHILLS (chills), PYREXIA (fever), NAUSEA (nauseous) and HEADACHE (throbbing/pressure headache) outcome was unknown.            No Concomitant medications were provided. .
right sided  jaw, facial, neck numbness; This is a spontaneous report received from a contactable consumer (patient). A 48-year-old female patient received second dose of BNT162B2 (FIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 21Jan2021 (Batch/Lot number was not reported) at single dose for COVID-19 immunization. Medical history included seasonal allergies. The patient's concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot # EH9899) via an unspecified route of administration at 2:00 on 28Dec2020 at single dose in left upper arm for COVID-19 immunization, and experienced neck was swollen with rash bilateral, neck palpitations and bounding pulse on 04Jan2021 at 9:00 (referred to AER#2021025542). CTA (computed tomography angiography) neck contrast showed no pulmonary embolism, no aneurysm or dissection, no pneumonia. Bilateral cartoid ultrasound on 11Jan2021 showed no mass or adenopathy or fluid detection. Post 2 weeks the patient experienced right sided jaw, facial, neck numbness and E.R visited on 05Feb2021. The outcomes of the events were unknown.  Information on Lot/ Batch number has been requested.; Sender's Comments: Linked Report(s) : PFIZER INC-2021025542 same patient/drug, different dose/AE
Injection site and surrounding arm felt like a rock; Dizziness; Overall achy; Mild wheezing; Chest tightness; Mild headache; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old, non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8737) via an unspecified route in the right arm on 01Apr2021 at 12:30 (at an age of 28-year-old) as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had medical history of asthma, anxiety, depression, ADHD (attention deficit hyperactivity disorder), peanut allergy and food allergy to legumes. The patient had known allergy to past drug VICODIN. Concomitant medications included birth control medications, montelukast (MANUFACTURER UNKNOWN), fluticasone propionate and salmeterol xinafoate (ADVAIR), esomeprazole (MANUFACTURER UNKNOWN) started on an unknown date for unknown indications. The patient did not receive any other vaccination within four weeks prior to the COVID vaccine. Post the vaccination, the patient was not tested for COVID-19. On 01Apr2021 at 15:00, the patient experienced fatigue, dizziness, overall achy, mild headache, mild wheezing and chest tightness. On 02Apr2021, the patient's injection site and surrounding arm felt like a rock. No treatment was given for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the events of injection site and surrounding arm felt like a rock, fatigue, dizziness, overall achy, mild headache, mild wheezing and chest tightness were recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
intense tingling in lips and tongue about 30 minutes after shot.   Lasted for over 18 hours.  Took a single Benadryl tablet at 5:00pm, monitored blood pressure.  Did not seek medical attention.  Next morning, lips still burning, no other side affects.
Information has been received from a consumer concerning her 4 year old female relative who on 08/29/01 was vaccinated with a dose of varicella virus vaccine live (site unknown). On 08/29/01, the pt vomited "all the way home". The child was reportedly "upset the rest of the day". On 08/31/01, the pt had spots and ran a temperature of 101.6 deg F. The following day the child had more spots on the face and neck. On 09/02/01, the pt had impertigo on her hand for which she was being treated with oral and topical antibiotics. The physician saw the pt on 09/03/01 and agreed that she agreed that she thought that the child had chicken pox. The pt had a total of about 10 spots on the back of both shoulders. The pt was still breaking out on 09/07/01. It was reported on 09/07/01 that the physician reported w/in the last few days that " the number of lesions are 12 now". On 09/07/01, the physician stated that the pt was asymptomatic.
last one attack my immune system and like to kill me; Initial information received on 07-Nov-2020 from Social Media regarding an unsolicited valid non-serious case from a patient.  This case involves a patient of unknown demographics who reported that last one attacked the immune system and like to kill the patient (immune system disorder), while the patient received vaccine influenza quadrival a-b intradermal vaccine [Fluzone].   The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided.   Concomitant medication was not reported.  On an unknown date, the patient received a dose of suspect influenza quadrival a-b intradermal vaccine (lot number and expiration date not reported) via unknown route in unknown administration site for prophylaxis vaccination.   On an unknown date, (latency unknown) after administration of suspect vaccine, patient reported the last one attacked the immune system and like to kill the patient (immune system disorder), after one the patient took in 1982 have not had even a sore throat since.   No relevant laboratory test was reported.   It was not reported if the patient received any corrective treatment.  At the time of reporting, outcome of the event was unknown.    There would be no information available on the batch number for this case.